Navigation Links
Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007

However, the Average Number of Days of Inpatient Therapy per Patient Treated with an Antibiotic for MRSA Decreased by 10 Percent, According to

New Data Released by Arlington Medical Resources

MALVERN, Penn., June 25 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA within U.S. acute care hospitals has increased from 2006 to 2007 by 8 percent. However, the average number of days of inpatient therapy per patient treated with an antibiotic associated with a positive culture for MRSA decreased by 10 percent.

The newly released edition of The U.S. Hospital Antibiotic Market Guide finds that the most common infections among these patients with a positive culture for MRSA are:

-- Skin/skin structure infections (46 percent of patients)

-- Systemic infections (19 percent of patients)

-- Lower respiratory infections (19 percent of patients)

Why Pharmaceutical Companies Need this Information

The U.S. Hospital Antibiotic Market Guide allows pharmaceutical companies to quantify the clinical utilization of hospital antibiotics at a highly granular level in the United States. It is the most comprehensive data available to gain insights into clinical usage and prescriber dynamics of hospital antibiotics, including gram positive and gram negative agents.

"With a large pipeline of late-stage anti-MRSA products, biopharmaceutical companies are demanding accurate information on MRSA usage patterns and trends so they can understand the current market and how treatments will evolve with the launch of new anti-MRSA drugs," said Joyce Wedemeyer, product director at AMR. "The U.S. Hospital Antibiotic Market Guide allows marketing, new product planning, market research and marketing teams to understand how antibiotic products are used in terms of combination therapy, types of infections, treatment intent and setting, and the types of specialists who are prescribing."

About U.S. Hospital Antibiotic Market Guide

The U.S. Hospital Antibiotic Market Guide is a semiannual syndicated clinical audit of antibacterial use in U.S. acute care hospitals. The audit is based on antibacterial census data from 250 demographically representative hospitals, plus a detailed clinical review of 11,000 randomly selected inpatient records yielding 25,000 antibiotic drug courses each 6-month audit cycle. The Hospital Antibiotic Market Guide is also available for France, Germany, Italy, Spain and the United Kingdom.

About AMR

AMR ( is a pharmaceutical market research firm serving the market intelligence needs of the pharmaceutical and diagnostic imaging industries since 1991. With offices in Malvern, PA and Brussels and affiliates in Tokyo, Seoul and Shanghai, AMR publishes syndicated audits for the United States, Italy, Germany, United Kingdom, France, Spain, China, Japan and Korea. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO Results: Oncologists Rank Genentech Number One
2. Nikon Instruments Receives Record Number of Entries for Nikon Small World
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. Nanotubes grown straight in large numbers
5. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
6. The neural basis of number sense in young infants
7. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
8. New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
9. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
10. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The United ... recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the USGA ... his or her work with turfgrass. , Clarke, of Iselin, N.J., is ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):